AHMEDABAD : Pharmaceutical major Zydus Cadila said on Monday it has got approval from Mexico's Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its one of its lead research candidate Desidustat to be tested in the management of COVID-19.The clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Sante Research Centre, a leading contract research organisation headquartered in Monterrey."The company will be conducting a phase 2b, multi-centre, open-label, randomised, comparator-controlled study to evaluate the efficacy and safety of Desidustat tablet for the management of Covid-19 patients," said Zydus in a statement.As a part of the study, 100 mg tablets of Desidustat will.